logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Polyarticular Juvenile Idiopathic Arthritis Rheumatoid Factor Negative

    Medications for Polyarticular Juvenile Idiopathic Arthritis Rheumatoid Factor Negative

    FiltersReset Filters
    26 results

    • abrilada

      (adalimumab-afzb)
      Pfizer Laboratories Div Pfizer Inc
      Usage: ABRILADA is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients.

    • actemra

      (tocilizumab)
      Genentech, Inc.
      Usage: ACTEMRA (tocilizumab) is indicated for treating moderately to severely active rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular and systemic juvenile idiopathic arthritis, severe cytokine release syndrome, and COVID-19 in hospitalized adults receiving systemic corticosteroids.

    • adalimumab-ryvk

      (adalimumab-ryvk)
      Quallent Pharmaceuticals Health LLC
      Usage: Adalimumab-ryvk is indicated for various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis, aiming to reduce symptoms and inhibit disease progression.

    • amjevita

      (adalimumab-atto)
      Amgen Inc
      Usage: AMJEVITA is indicated for treating various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients, depending on the specific condition.

    • avtozma

      (tocilizumab)
      CELLTRION USA, Inc.
      Usage: AVTOZMA® (tocilizumab-anoh) is indicated for adults with moderately to severely active rheumatoid arthritis, giant cell arteritis, and hospitalized adults with COVID-19. It also treats active polyarticular and systemic juvenile idiopathic arthritis in patients aged 2 years and older.

    • cimzia

      (certolizumab pegol)
      UCB, Inc.
      Usage: CIMZIA is indicated for treating moderately to severely active Crohn's disease, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis in patients aged 2 and older, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and moderate-to-severe plaque psoriasis in adults.

    • cyltezo

      (adalimumab-adbm)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: CYLTEZO is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients aged 2 and older.

    • enbrel

      (etanercept)
      Immunex Corporation
      Usage: Enbrel is indicated for reducing signs and symptoms in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, chronic moderate to severe plaque psoriasis, and active juvenile psoriatic arthritis in patients aged 2 and older, with or without methotrexate.

    • humira

      (Adalimumab)
      AbbVie Inc.
      Usage: HUMIRA is indicated for multiple conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis, in adult and pediatric patients, depending on the specific condition.

    • jylamvo

      (Methotrexate)
      SHORLA ONCOLOGY INC.
      Usage: JYLAMVO is indicated for treating acute lymphoblastic leukemia in adults and pediatric patients, mycosis fungoides, relapsed non-Hodgkin lymphomas, rheumatoid arthritis in adults, polyarticular juvenile idiopathic arthritis in pediatrics, and severe psoriasis in adults.